Moderna shares jump after better than expected ER report.

Up by around 9% now today.

In addition to the ER report, The FDA is due to make its decision on Moderna's RSV vaccine shot in less than two weeks. Moderna hopes to launch its vaccine for older adults this fall.

如果获得批准，这将是Moderna继Covid疫苗之后的第二个商业产品。

“我们超级兴奋的原因有很多，”他说。“这是我们的第二个产品，所以我认为它有助于验证mRNA，或Moderna，平台。我认为从mRNA的角度来看，这是世界上第二个产品，所以我们很受鼓舞，因为我们预计在今年上半年获得批准。”Chief Financial Officer Jamey Mock told Investor's Business Daily in an interview.

 

这不是投资建议，YMYD

 

 

 

 

 

所有跟帖： 

• I predict its RSV vac is going to be a commercial flop -君子花农- ♂ (0 bytes) () 05/02/2024 postreply 10:45:40